* If you want to update the article please login/register
This prospective, single-arm review is intended to explore the causes that lead to a lack of response to influenza vaccine in older adults following the establishment of the FluVax3 cohort of healthy older adults. The investigators will perform comprehensive profiling of blood antibodies and immune cells over time, as well as specific age-related immune changes with vaccine responder or non-responder status in this study. This will help the investigators develop a universal influenza vaccine by identifying biological pathways that can be targeted to raise vaccine safety and help the investigators develop a universal influenza vaccine. A total of sixty-six healthy adults aged 65 years and older who have not received influenza vaccination for the approaching influenza season will be included in the study and vaccinated with influenza vaccines approved by the U. S. Food and Drug Administration and recommended by the Centers for Disease Control and Prevention for individuals aged 65 to 65 years old. The study sample will be drawn from the population of healthy older people in UConn Health in Farmington, CT, each year, and one final research visit over three years. In addition, determining the mechanistic relationships between the correlates of three different influenza vaccines will aid in the development of a universal influenza vaccine, which is a main focus of NIAID's influenza research program.
Source link: https://clinicaltrials.gov/ct2/show/NCT05518500
In a pragmatic, open-label, registry-based strategy, we want to randomize 40,000 Danish citizens aged 65-79 years for recruitment and randomization of data collection in a cost-effective, universally distributed framework.
Source link: https://clinicaltrials.gov/ct2/show/NCT05048589
On the immunization schedule of day 0,28 in each group, the participants in phase u2160's randomization will be randomly assigned to 4 groups in a 2:2:1 ratio; respectively.
Source link: https://clinicaltrials.gov/ct2/show/NCT05245552
We'll design this clinical trial to determine its immunogenicity and safety in order to determine the possibility of simultaneously administering EV71 vaccine and flu vaccine. Subjects aged 6 to 11 months old are divided into two experimental groups and two control groups, with one experimental group divided into two control groups. One dose of EV71 vaccine and one dose of influenza vaccine will be simultaneously administered to 378 participants from the experimental group. They will both get their second dose of EV71 vaccine and influenza vaccine one month later. Two doses of EV71 vaccine will only be administered to 378 subjects from the control group A. Two doses of influenza vaccine will only be administered from the control group B's control group B. Blood samples are obtained before the first vaccination and one month after the second vaccination.
Source link: https://clinicaltrials.gov/ct2/show/NCT04091880
Severe acute respiratory syndrome coronavirus is a highly infectious and pathogenic coronavirus that has spread quickly and globally, and Influenza is a worldwide public health concern, responsible for significant morbidity and mortality. The seasonal influenza vaccines used in this study are quadrivalent and quadrivalent or equivalent. As measured by Spiked-linked Immunosorbent Assay antibody titers against each of the four influenza vaccine strains, the aim is to demonstrate that the concomitant administration of either seasonal quadrivalent influenza vaccine or Ad26. COV2. S vaccine alone, as measured by HI titers against each of the four influenza vaccine strains at 28 days after the introduction of the Ad26. COV2. S vaccine or Ad16. COV2. S vaccine alone, as measured by titer.
Source link: https://clinicaltrials.gov/ct2/show/NCT05091307
In participants who have received three prior doses of BNT162b2 — first dose taken 1 month before Visit 1 – the third dose will be at least 90 days before arrival at Visit 1.
Source link: https://clinicaltrials.gov/ct2/show/NCT05310084
On day 0, vaccine-primed subjects will receive a single 0. 5 million dose of Sinovac-QIV or Vaxigrip Tetra-QIV. Both day 0 and day 28, respectively, will receive two 0. 5 ml doses of Sinovac-QIV or Vaxigrip Tetra-QIV. Subjects who are 3-8 years of age had received u22652 doses of influenza vaccine at least 4 weeks apart or who are u22659 years old are classified as vaccine-prime. ' Subjects who are 3-8 years old or older had before receiving a 2 dose of influenza vaccine are considered "vaccine-unprimed. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT05431725
Among adults aged 18-64 years, this randomized, active comparator trial will compare the clinical results of recombinant influenza vaccine to standard-dose eggs-based inactivated influenza vaccine in adults aged 18 to 64 years. To minimize the study's outcome measurement, designated study staff administering vaccines will be aware of study arm assignment and will not be involved with research design to avoid involvement in study findings. Participants will be sent weekly text messages or emails alerting of new onset of ILI symptoms to help them understand the electronic surveillance protocols and keep them informed about the study before it is widely distributed influenza viruses in the community. Participants may also self-collect mid-turbinate nasal swabs, or drop off swabs at designated locations for shipment to a central laboratory as soon as the first week of December, whether national and/or state influenza surveillance systems indicate that influenza viruses have begun circulating in the United States or earlier this week. Participants who experience ILI symptoms during the surveillance period, or sooner than the first week of December, will complete follow-up questionnaires to provide detailed information about their illnesses during the influenza virus circulation period or earlier than the first week of December. Electronic surveillance and nasal swab collection will persist until local influenza virus circulation is complete, with the possibility of resuming surveillance if further outbreaks of influenza virus circulation occur during each trial season in May.
Source link: https://clinicaltrials.gov/ct2/show/NCT05514002
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions